Shoulder Innovations Delivers Exceptional Q4 2025 Results, Sets Sights on 2026 Growth
Shoulder Innovations has reported exceptional financial results for its fourth quarter and full-year 2025 earnings call. The company's CEO, Rob Ball, and CFO, Jeff Points, showcased the firm's impressive performance, driven by accelerated market adoption of its advanced implant systems across a growing base of surgeon customers.
Revenue for Q4 2025 hit $14.4 million, reflecting a 65% year-over-year increase and a 23% sequential jump. The full-year revenue totaled $47.3 million, up 50% from the previous year. Gross margins also remained strong at 76.7% for Q4 and 76.5% for the full year, demonstrating the company's commitment to enhancing profitability.
The impressive performance has left Shoulder Innovations highly confident in its ability to sustain commercial progress into 2026 and beyond. As a result, the company is initiating full-year 2026 revenue guidance of $62 million-$65 million, representing growth of 31%-37% year-over-year.
Shoulder Innovations' CEO, Rob Ball, emphasized that the company's performance and accelerating business momentum exiting Q4 leave it well-positioned to achieve this growth in 2026. He highlighted three key strategic priorities driving above-market growth: driving adoption among new surgeons, increasing penetration in existing surgeon customer bases to boost procedural volume, and adding products to its portfolio to address remaining unmet needs of patients and surgeons.
The company's focus on innovation, driven by a strong team, has solidified its position as an industry leader in the shoulder space. Shoulder Innovations' dedication to positively impacting thousands of patients and the shoulder specialists who care for them has been at the forefront of its efforts, with continued market adoption of its implant systems demonstrating its commitment to this goal.
The company's CEO, Rob Ball, noted that 2025 was a transformational year for Shoulder Innovations. He expressed pride in the team's accomplishments, including adding new surgeon customers at an accelerated pace and beginning their journey as a public company. The firm's exceptional performance has set it up for continued success in 2026.
